Clinical Trial Update: Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating imatinib mesylate for recurrent brain tumors completed, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Oligodendroglioma
• Brain Neoplasm
• Mixed Glioma
• Oligodendroglioma

Drugs mentioned

• Imatinib mesylate (Imatinib)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Adult Anaplastic Oligodendroglioma, Adult Mixed Glioma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-10-06